CD4 News and Research

RSS

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Researchers ascertain whether the SARS-CoV-2 Omicron variant evades cellular immunity.

3 Jan 2022

Omicron infection induces cross-reactive immune responses

New research revealed that vaccine-breakthrough infections might elicit cross-reactive bNAbs against all variants of concern.

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

Vaccine-induced T-cells vs. Omicron well preserved compared with all variants

A team of international scientists has recently revealed that T cell responses induced by coronavirus disease 2019 (COVID-19) vaccines are able to cross-recognize different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is currently available on the bioRxiv* preprint server.

30 Dec 2021

Reviewing myocarditis and pericarditis in immunosuppressed individuals following COVID-19 mRNA vaccination

A new study did not conclusively correlate the incidence of myocarditis or pericarditis with mRNA vaccination against SARS-CoV-2.

30 Dec 2021

Exploring the importance of selenium in COVID-19 patients

In a new study, researchers reviewed research on the role that selenium could play in protecting individuals against coronavirus disease 2019.

29 Dec 2021

Exploring why children have milder COVID-19 infections compared to adults

A new study has revealed that an activated pre-exposure innate interferon response in airways together with significantly reduced systemic interferon-stimulated populations are associated with relatively milder severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children.

23 Dec 2021

T-cell response to Omicron after an mRNA COVID vaccine booster

In a recent prospective observational study posted to the medRxiv* preprint server, researchers determined Omicron variant-associated T cell responses before and after a third dose of messenger ribonucleic acid (mRNA) vaccination against coronavirus disease (COVID-19) in anti-CD20-treated multiple sclerosis (MS) patients.

22 Dec 2021

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Researchers developed four distinct recombinant vesicular stomatitis virus (rVSV)-based bivalent vaccines against SARS-CoV-2 and influenza virus.

22 Dec 2021

Effect of T cell reactivity in COVID-19 infection and vaccination

Researchers recently developed an immunodiagnostic T cell assay to classify T cell immune responses of the subjects based on their coronavirus disease 2019 infection and vaccination history.

21 Dec 2021

Booster shots improve CD8+ T cell response to SARS-CoV-2 in animal model

In a new study, published on the bioRxiv* preprint server, scientists showed in a mice model that three doses of the same synthetic peptide vaccine, eliciting an exclusive CD8+ T cell response against one SARS-CoV-2 Spike epitope, protected against lethal SARS-CoV-2 infection, in the absence of neutralizing antibodies. Researchers also showed that the third dose resulted in superior generation of effector-memory T cells in the circulation and tissue-resident memory T (TRM) cells.

20 Dec 2021

Primary responses to SARS-CoV-2 in COVID-19 naïve vaccinees

Researchers evaluated primary responses in SARS-CoV-2-naïve vaccinees, as well as secondary responses in the SARS-CoV-2-infected vaccines, and observed a clear set of differences in their clinical symptoms, antibody levels, and cellular and mucosal immune responses.

17 Dec 2021

ACTG announces the launch of clinical trial to evaluate new CMV vaccine in adults

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5355, a clinical trial studying a new cytomegalovirus (CMV) vaccine in adults with both HIV and CMV.

16 Dec 2021

T cell responses remain broadly robust against Omicron variant of SARS-CoV-2

A new study highlights the significance of robust T cell responses in preventing severe omicron infections.

16 Dec 2021

Assay for the identification of SARS-CoV-2 Spike reactive T and B cells

An interesting new paper presents a new assay for B and T lymphocytes in individuals infected with SARS-CoV-2.

14 Dec 2021

New mRNA vaccine platform provides stronger protection against SARS-CoV-2 delta variant

A group of researchers from various institutions developed a nucleoside-modified mRNA vaccine that encodes the SARS-CoV-2 N protein (mRNA-N) and is formulated in lipid nanoparticles for this investigation (LNP).

14 Dec 2021

Determination of the effectiveness of COVID-19 vaccination using T cell receptor repertoire

A new study published on the bioRxiv preprint server has hypothesized that T cell receptors (TCR) repertoire can measure the response to vaccines, as it would identify the TCR of clones that respond to the vaccination.

13 Dec 2021

MV130 immunotherapy boosts natural and vaccine-induced SARS-CoV-2 immunity in mice

A new mouse study found that intranasal administration of MV130 protected against severe acute respiratory syndrome coronavirus 2.

13 Dec 2021

New insights about COVID-19 vaccination rates among people living with HIV

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that insights around COVID-19 vaccination rates among people living with HV have been published in the Journal of Infectious Diseases.

10 Dec 2021

Insight into immune cell communication may pave the way for new cancer vaccines

In the past decade, immunotherapy has helped save the lives of many cancer patients, many with lung cancer, who might have otherwise faced almost certain death sentences.

9 Dec 2021